DBV Technologies (DBV Technologies) Pre-Tax Income : $-79.46 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. DBV Technologies's pretax income for the three months ended in Mar. 2024 was $-27.30 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was $-79.46 Mil. DBV Technologies's pretax margin was %.

During the past 13 years, DBV Technologies's highest Pretax Margin was -11384.62%. The lowest was -22087.19%. And the median was -16735.91%.

DBV Technologies Pre-Tax Income Historical Data

The historical data trend for DBV Technologies's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Pre-Tax Income Chart

DBV Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-171.40

-159.57

-98.19

-96.20

-72.72

DBV Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial															-20.56	-24.23	-16.74	-11.19	-27.30

Competitive Comparison of DBV Technologies's Pre-Tax Income

For the Biotechnology subindustry, DBV Technologies's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Pre-Tax Income falls into.

DBV Technologies Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

DBV Technologies's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-76.533	+	0	+	0	+	0	+	3.814
	=	-72.72

DBV Technologies's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-28.559	+	0	+	0	+	1.261	+	0.0010000000000012
	=	-27.30

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-79.46 Mil.

DBV Technologies (NAS:DBVT) Pre-Tax Income Explanation

DBV Technologies's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-27.297	/	0
	=	%

During the past 13 years, DBV Technologies's highest Pretax Margin was -11384.62%. The lowest was -22087.19%. And the median was -16735.91%.

DBV Technologies Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies (DBV Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

0QAJ:UK DBV:France DBV:Germany

Address

177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120

Website

http://www.dbvtechnologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Executives

Pharis Mohideen	officer: Chief Medical Officer	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Virginie Boucinha	officer: Chief Financial Officer	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Michael Goller	director	C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Daniel Tasse	director, officer: Chief Executive Officer	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809